Research at the Institute of Pharmacy and Molecular Biotechnology (IPMB) at the Ruprecht-Karls-University of Heidelberg focuses on the development, investigation, and application of drugs and bioactive compounds, as well as on the elucidation of molecular and cellular mechanisms of action. This research integrates experimental approaches of chemistry, molecular and cellular biology, pharmacology, bioinformatics, and pharmaceutics. Main research areas of IPMB include nucleic acids as tools and drug targets, development of new anti-infective drugs, research on neurodegenerative diseases as well as drug targeting and transport.
Role within EURAS
For EURAS, the Institute of Pharmacy and Molecular Biotechnology (IPMB) develops surface modified liposomal drug carriers loaded with Rosuvastatin to cross the blood brain barrier and enhance brain uptake of the statin.